Peptide Hormone News and Research

RSS

Metals bind to and influence peptide involved in insulin production

Metals such as zinc, copper and chromium bind to and influence a peptide involved in insulin production, according to new work from chemists at the University of California, Davis.

20 May 2019

Sphingotec reports new applications of bio-ADM at 39th ISICEM

Diagnostics company sphingotec GmbH reports novel applications of bio-ADM, the very first biomarker capable to diagnose the onset of septic shock, allowing physicians earliest life-saving therapeutic interventions in sepsis critical care.

20 Mar 2019

Adrenomedullin could serve as biomarker, therapeutic target in disorders caused by leaky blood vessels

Disorders caused by a leaky vasculature are more common than most people think. Despite ICU treatment, one third of the 27 million patients globally that suffer from sepsis, and up to 20% of the more than 5 million US patients with congestive heart failure die every year from their condition.

5 Jan 2018

Research sheds light on how to improve production of key diabetes cells

Beta cells release insulin in your blood, but when you suffer from Type 1 diabetes, you hardly have any of them left in your body. This is because the immune system attacks the beta cells.

21 Sep 2017

Good blood microcirculation linked to longevity

Human longevity has been previously linked by researchers to genetic factors, calorie restriction, and certain life-style factors such as physical activity or the Mediterranean diet.

6 Sep 2016

Levels of peptide hormone adropin linked to carbohydrate intake

In research featured in the August edition of Obesity, Saint Louis University investigator Andrew Butler, Ph.D., and his team report that levels of the peptide hormone adropin vary based on carbohydrate consumption and appear to be linked to lipid metabolism.

27 Jul 2016

New promising therapy may improve curative potential of islet transplant for Type 1 diabetes

New research suggests pretreating cells with a peptide hormone may improve the success rate of pancreatic islet cell transplants, a procedure that holds great promise for curing Type 1 diabetes. The results will be presented Saturday, April 2, at the Endocrine Society's annual meeting, ENDO 2016, in Boston.

4 Apr 2016

Older people could be at greater risk for negative consequences of consuming high-salt diet

Aging is associated with a number of changes that cause the body to function less efficiently, including the way the body controls water and sodium levels. Research has shown that as humans and animals age, they are less able to regulate sodium and water retention, urine concentration and thirst compared to their younger counterparts.

9 Feb 2016

Study provides new insight into complex interchange that can raise blood levels of fat in type 1 diabetes

Researchers have new insight into the complex interchange that can raise blood levels of unhealthy lipids, or fat, in type 1 diabetes, and early evidence that a drug under study to block cancer cell growth can restore healthier levels.

8 Feb 2016

New book provides authoritative overview of neuroendocrine tumors

Neuroendocrine tumors (NETs) originate from diffuse neuroendocrine cells that are dispersed throughout the body, predominantly in the gastrointestinal tract, islets of Langerhans in the pancreas and the bronchopulmonary system.

31 Aug 2015

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, a biopharmaceutical company, and Actavis plc, a leading global pharmaceutical company, announced today the initiation of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes.

8 Apr 2015

University of Alberta researcher named winner of A.S.P.E.N.'s 2015 Harry M. Vars Award

David Lim, MD, CM, of the University of Alberta has been named the winner of the 2015 Harry M. Vars Award by the American Society for Parenteral and Enteral Nutrition. The award is for his research on parenteral nutrition associated liver disease (PNALD) in infants, which was presented at A.S.P.E.N.'s Clinical Nutrition Week conference in Long Beach, California, February 14 to 17.

19 Feb 2015

University of Alberta's David Lim named recipient of Research Trainee Award by A.S.P.E.N.

David Lim, MD, CM, of the University of Alberta has been named a Research Trainee Award recipient by the American Society for Parenteral and Enteral Nutrition. The award is for his research on parenteral nutrition associated liver disease (PNALD) in infants that he will present at A.S.P.E.N.'s Clinical Nutrition Week conference in Long Beach, California, February 14 to 17.

6 Feb 2015

Adropin hormone offers a promising treatment option for type 2 diabetes

In a study published in Molecular Metabolism, a SLU researcher has found that adropin, a hormone that regulates whether the body burns fat or sugar during feeding and fasting cycles, can improve insulin action in obese, diabetic mice, suggesting that it may work as a therapy for type 2 diabetes.

30 Jan 2015

Scientists find that blocking hormone reduces stress-induced infertility in female rats

University of California, Berkeley, scientists have discovered that chronic stress activates a hormone that reduces fertility long after the stress has ended, and that blocking this hormone returns female reproductive behavior to normal.

13 Jan 2015

New approach promises better drugs for diabetes and osteoporosis

By swapping replacement parts into the backbone of a synthetic hormone, UW-Madison graduate student Ross Cheloha and his mentor, Sam Gellman, along with collaborators at Harvard Medical School, have built a version of a parathyroid hormone that resists degradation in laboratory mice.

18 Jun 2014

Georgia Regents Medical Center explores new treatment for Parkinson's disease-related constipation

Georgia Regents Medical Center is among about a dozen centers nationally exploring the potential of a new drug that may offer relief to people with Parkinson's who have failed standard approaches to treating constipation.

5 Mar 2014

Retrophin to acquire privately-held company, Kyalin Biosciences

Retrophin, Inc. today announced that it will acquire privately-held Kyalin Biosciences, Inc., an early-stage company based in San Diego, CA, that is developing therapies targeting the core symptoms of autism and related conditions.

12 Dec 2013

Retrophin signs agreement with Novartis for exclusive U.S. license for Syntocinon Nasal Spray

Retrophin, Inc. today announced that it has signed an agreement with Novartis Pharma AG for an exclusive U.S. license for Syntocinon Nasal Spray, the intranasal formulation of a synthetic version of the naturally occurring peptide hormone oxytocin, for an upfront payment of $5.0 million plus milestone payments and royalties.